Our study findings are consistent with previous reports in which DNR/doxorubicin activated the NF-κB signaling pathway and subsequently conferred chemotherapy drug resistance to malignant cells in breast and ovarian cancer (Vasiyani et al. 2022; Lee et al. 2018; Fang et al. 2014; Esparza-López et al. 2013). Here, NFKB1 is linked to ovarian cancer.